Department of Radiation Oncology, Washington University School of Medicine, 4921 Parkview Place, St Louis, MO 63110, USA.
Phys Med Biol. 2010 Jan 7;55(1):65-82. doi: 10.1088/0031-9155/55/1/005.
Electromagnetic tracking technology is primarily used for continuous prostate localization during radiotherapy, but offers potential value for evaluation of dosimetric coverage and adequacy of treatment for dynamic targets. We developed a highly automated method for daily computation of cumulative dosimetric effects of intra- and inter-fraction target motion for prostate cancer patients using fiducial-based electromagnetic tracking. A computer program utilizing real-time tracking data was written to (1) prospectively determine appropriate rotational/translational motion limits for patients treated with continuous isocenter localization; (2) retrospectively analyze dosimetric target coverage after daily treatment, and (3) visualize three-dimensional rotations and translations of the prostate with respect to the planned target volume and dose matrix. We present phantom testing and a patient case to validate and demonstrate the utility of this application. Gamma analysis of planar dose computed by our application demonstrated accuracy within 1%/1 mm. Dose computation of a patient treatment revealed high variation in minimum dose to the prostate (D(min)) over 40 fractions and a drop in the D(min) of approximately 8% between a 5 mm and a 3 mm PTV margin plan. The infrastructure has been created for patient-specific treatment evaluation using continuous tracking data. This application can be used to increase confidence in treatment delivery to targets influenced by motion.
电磁跟踪技术主要用于放射治疗过程中的前列腺连续定位,但也具有评估动态目标剂量覆盖和治疗充分性的潜在价值。我们开发了一种基于基准点的电磁跟踪的高度自动化方法,用于计算前列腺癌患者的内部分和分次间目标运动的累积剂量效应。编写了一个利用实时跟踪数据的计算机程序,用于(1)前瞻性确定接受连续等中心定位治疗的患者的适当旋转/平移运动限制;(2)回顾性分析每日治疗后的剂量目标覆盖情况;(3)可视化前列腺相对于计划靶区和剂量矩阵的三维旋转和平移。我们展示了体模测试和一个患者病例,以验证和演示该应用的实用性。我们的应用程序计算的平面剂量的伽马分析显示,精度在 1%/1mm 以内。对患者治疗的剂量计算显示,在 40 多个分次中,前列腺的最小剂量(D(min))变化很大,在 5mm 和 3mm PTV 边界计划之间,D(min)下降了约 8%。已经为使用连续跟踪数据进行患者特定治疗评估创建了基础设施。该应用程序可用于提高对受运动影响的目标进行治疗的信心。